PROMOMED expands its portfolio of incretin drugs in Belarus
25.02.2022
25.02.2022
On February 22, 2022, the Russian Ministry of Health approved the 15th version of the Interim Guidelines for the Prevention, Diagnosis and Treatment of new Coronavirus infection. The list of possible medications for the treatment of COVID-19 in adults includes 6 drugs, two of which are produced by Promomed Group of Companies — Esperavir® (molnupiravir) and Areplivir® (favipiravir) in two dosage forms. They have already proven themselves to be effective in the treatment of coronavirus infection and covid-19 syndrome.
Complications and consequences of coronavirus infection are no less dangerous for patients. In this regard, Promomed Group pays great attention to the development and production of drugs aimed at complex therapy, focusing on solving global medical problems and saving lives. The company's anticoagulant portfolio already includes effective anticoagulants Enoparin® and Thrombophores® forte, Radamin® RNA-based Viro and a number of antibiotics. All these medicines are also included in the current recommendations of the Ministry of Health of the Russian Federation, published on the official website.
Stay informed
Stay informed
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office